Skip to main content

Clover Bio Starts Construction of R&D Center in Zhangjiang Hi-Tech Park

Chengdu Clover Biopharma started construction of a Shanghai R&D Center to develop novel vaccines and biologic therapies. The facility, which will be built on  25,000 square meters of land, will contain a state-of-the-art preclinical research laboratory, manufacturing process development labs and a GMP pilot manufacturing plant. The facility will be located in Zhangjiang Biotech and Pharmaceutical Industrial Base in Zhangjiang Hi-Tech Park. Clover also announced the start of clinical trials of a booster shot of its COVID-19 vaccine following two original doses. More details.... Stock Symbol: (HK: 02197) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.